Figure 6.

In vivo efficacy of the anti-IL13Rα2 ADC in the A375 xenograft model. A375 tumor-bearing animals were randomized when their tumors reached an average of 330 mm³ in size and treated with vehicle, isotype control 8.8-mAb-ADC (3 mg/kg), or the anti-IL13Rα2 ADC (0.3, 1.0 and 3.0 mg/kg) in a q4d × 4 treatment schedule. (a) Tumor growth inhibition curves demonstrate a dose response in anti-tumor effect with anti-IL13Rα2-ADC. A significant difference in tumor volume was observed in the 1 and 3 mg/kg groups compared to Vehicle on day 14 when the vehicle group animals were euthanized. Tumors treated with 8.8-mAb-ADC (3 mg/kg) and anti-IL13Rα2-ADC (0.3 mg/kg) were not statistically different on day 14, compared to the vehicle group. (b) Spaghetti plot shows no difference in tumor growth curves between mice treated with Vehicle and 8.8-mAb-ADC. (c) Spaghetti plot shows no difference in tumor growth curves between mice treated with Vehicle and anti-IL13Rα2-ADC at 0.3 mg/kg, although one treated mouse showed a complete response (CR). (d) Spaghetti plot showed a significant difference in tumor growth curves between mice treated with anti-IL13Rα2-ADC at 1.0 mg/kg, with 4 CRs, and Vehicle. (e) Spaghetti plot showed a significant difference in tumor growth curves between mice treated with anti-IL13Rα2-ADC at 3.0 mg/kg, with 9 CRs, and Vehicle. **, p-value < 0.001. N = 9– 10 per group